Camblong Jurgi sold 8,500 shares of SOPHiA GENETICS SA at $7.76 for −$65.9k on Nov 10, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Executive Chairman
Executive Chairman
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$65,948.10Shares × reported price
Shares traded
8,500Ordinary Shares
Price per share
$7.76Reported price. Read footnotes for ranges.
% of reported position traded
0.25%This security and ownership context
Holdings after
3,378,650Direct
Trade date
Nov 10, 2026Sell
Filed
Nov 12, 2026, 4:01 PM ET2-day reporting delay
Accession
0001840706-26-000357Code S · Transaction 398652
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 3,387,150 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

SOPH price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SOPH · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −0.7%1w ago −7.4%1d ago +0.4%
Returns since7d30d90d180d1y

Footnotes in full

F1: Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.52 to $7.89, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.